In the market the company is trading down by -1.96 percent from yesterday’s close. The stock is trading at $1.50 a bit lower than the 50 day moving average of $1.89 and barely below the 200 day moving average of $2.99. The 50 day moving average moved down $-0.39 and the 200 day average went down by -49.91%.
Genesis Healthcare, Inc. (NYSE:GEN) has been the object of insider selling activity recently. COO Paul David Bach let go of 2,769 shares at an average price of $1.61 on June 7th. The COO now owns $835,505 of the stock as recorded in a recent Form 4 SEC filing. Sr VP Thomas Divittorio disclosed the sale of 2,900 shares of GEN stock. The shares were purchased at an average price of $1.61. The Sr VP now owns $1,049,751 of the stock according to the SEC filing.
Daniel Allen Hirschfeld, COO Int’l. Oper. & Rehab Svcs. sold $4,661 worth of shares at an average price of $1.61 on Wed the 7th. That brings Hirschfeld’s holdings to $1,016,016 per an SEC filing yesterday.
Genesis Healthcare, Inc., launched on October 21, 2005, is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services. As of December 31, 2016, the Company offered inpatient services through its network of 499 skilled nursing and assisted/senior living facilities across 34 states, consisting of 473 skilled nursing facilities and 26 stand-alone assisted/senior living facilities. Its services focus primarily on the medical and physical issues facing elderly patients and are provided by its skilled nursing companies, assisted or senior living communities, integrated and third-party rehabilitation therapy business, and other ancillary services..
These funds have also shifted positions in (GEN). Goldman Sachs Group Inc augmented its position by buying 57,065 shares an increase of 201.7% as of 03/31/2017. Goldman Sachs Group Inc now holds 85,362 shares worth $225,000. The total value of its holdings increased 87.5%. As of the end of the quarter State Street Corp had bought a total of 17,314 shares growing its position 2.4%. The value of the total investment in Genesis Healthcare, Inc. went from $3,124,000 to $1,987,000 decreasing 36.4% for the reporting period.
Panagora Asset Management Inc added to its stake by buying 62,554 shares an increase of 14.5% in the quarter. Panagora Asset Management Inc now controls 494,379 shares with a value of $1,305,000. The value of the position overall is down by 28.9%. Invesco Ltd. expanded its ownership by buying 126,545 shares an increase of 13,921.3%. Invesco Ltd. controls 127,454 shares valued at $336,000. The value of the position overall is up by 16,700.0%.
On July 6 analysts at Cantor Fitzgerald began coverage of the stock with a rating of “Overweight”. On November 21 the company was downgraded from “Outperform” to “Sector Perform” with a current price target of $3.50 by RBC Capital.
On May 16 the stock rating was downgraded to “Underperform” from “Neutral” in a report from Bank of America. UBS downgraded the stock and lowered the price target on February 8 cutting the price target from $0.00 to $1.50 and changing the rating from “Neutral” to “Sell”.
On February 8 the company was downgraded from “Neutral” to “Sell” and a price target of $1.50 was set in an announcement from UBS. January 26 investment analysts at Susquehanna made no change to the company rating of “Neutral” but lowered the price target from $5.50 to $2.75.
In the last earnings report the EPS was $-1.47 and is projected to be $-1.27 for the current year with 92,731,000 shares currently outstanding. Next quarter’s EPS is expected be $-0.30 with next year’s EPS anticipated to be $-1.08.